2016 Biomax Symposium: Bringing big and complex data into clinical practice

24 June 2016, Martinsried, Germany.
Biomax announces the 2016 Biomax Symposium on "Bringing Big and Complex Data into Clinical Practice" that will take place in Martinsried (near Munich), Germany. This year's Biomax Symposium focuses on how clinical practice and patient treatment can benefit from big and complex data. It will cover the challenges and requirements that need to be addressed in a clinical setting: from gathering big data, guaranteeing data security in daily practice and fostering feedback between complex clinical data and research, to learning from the data to make better treatment decisions. In a nutshell, the symposium will cover using big and complex data to treat the individual with the knowledge of all.

Biomax has hosted this biennial event since 2012 to facilitate the discussion between clinical management and practitioners, pharma, "Big Data" researchers, health insurance payers, public health and government representatives, funding providers, as well as patient representatives. Through the symposium Biomax hopes to share their own and other experiences in implementing such programs. Past symposia have been a popular forum for these important players to learn from each other and discuss the way forward.

Invited speakers and panel discussion participants are leaders from clinical research, healthcare organizations, international research projects and government. The opening session includes presentations by:

  • Prof. Dr. Emiel Wouters, Department of Respiratory Medicine, University Medical Centre, Maastricht
  • Henning Schneider, CIO at the University Medical Center Hamburg-Eppendorf
  • Prof. Dr. Hans-Werner Mewes, School of Life Sciences, Technische Universität München

The symposium is free of charge.

For further information and to register, please visit:
http://www.biomax.com/symposiums/biomax-symposium-2016/

About Biomax
Biomax Informatics AG is a leader in the development of computational solutions for the life sciences. Biomax provides the BioXM™ Knowledge Management Environment and other computational solutions, including the Viscovery® data-mining technology, for better decision making and knowledge management in biomarker identification, patient stratification and targeted medicine. They help customers generate value by integrating information from proprietary and public resources to enable a knowledge-based approach to developing innovative life science products. Biomax’s worldwide customer community includes medical clinics, research organizations and companies that are successful in drug discovery, diagnostics, fine chemicals, food and plant production and healthcare.

Most Popular Now

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

Addressing social and cultural drivers of type 2 d…

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and ...

Evidence mounts linking aspirin to lower risk of o…

Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported ta...